DYSPORT

LOE Approaching

botulinum toxin type a

BLAINJECTIONINJECTABLE
Approved
Apr 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Acetylcholine Release Inhibitors

Pharmacologic Class:

Acetylcholine Release Inhibitor

Clinical Trials (5)

NCT06293300Phase 2Recruiting

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

Started Sep 2024
50 enrolled
Traumatic Brain Injury
NCT06068855Phase 3Completed

A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants

Started Oct 2023
249 enrolled
Masseter Muscle Prominence
NCT06047444Phase 3Active Not Recruiting

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Started Oct 2023
759 enrolled
Chronic Migraine
NCT06047457Phase 3Active Not Recruiting

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Started Sep 2023
751 enrolled
Episodic Migraine
NCT05224349N/ACompleted

Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.

Started May 2022
121 enrolled
Post-Stroke Chronic Upper Limb Spasticity